陽光諾和(688621.SH):藥品NHKC-1獲得藥物臨牀試驗批准通知書
格隆匯8月5日丨陽光諾和(688621.SH)公佈,公司獲得國家藥品監督管理局的《藥物臨牀試驗批准通知書》,並將於近期開展該品臨牀試驗。該藥品名稱為NHKC-1。
公司開發的NHKC-1,屬於含有均已在國內外上市活性成份的新複方製劑,註冊分類為化學藥物2.3類,臨牀用於高血壓治療。該品獲得臨牀試驗默示許可後,北京陽光諾和藥物研究股份有限公司將按照國家藥品註冊的相關規定和要求組織實施該品的臨牀試驗,待臨牀試驗成功後按程序申報相關產品的生產。
若獲批上市,將為患者提供新的用藥選擇。該品屬於公司自主研發,開發到一定階段會擇機向客户推薦,公司自身並不涉及生產、銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.